仁和藥業(000650.SZ):共有222個產品進入國家醫保目錄
格隆匯 1 月 13日丨仁和藥業(000650.SZ)公佈,近期,根據國家醫療保障局、人力資源社會保障部聯合下發的關於印發《國家基本醫療保險、工傷保險和生育保險藥品目錄》的通知(醫保發[2020]53號),公司共有222個產品進入國家醫保目錄,其中化藥110個,甲類69個,乙類41個,重點品種有:苯磺酸氨氯地平片、格列齊特緩釋片、複方甘草片、氫溴酸右美沙芬糖漿等;中成藥112個,甲類49個,乙類63個,重點品種有:大活絡膠囊、大活絡丸、安宮牛黃丸、六味地黃丸、通竅鼻炎膠囊、小兒咽扁顆粒、強力枇杷膠囊等。
與前一版目錄相比,公司產品新進入3個品種,退出1個品種。
公司主要品種和新進產品入選國家醫保目錄,將對今後的藥品銷售和長遠發展產生積極作用,退出目錄的乾酵母片是公司OTC營銷品種,非醫院招投標渠道經營品種。敬請投資者理性投資,注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.